Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07664696
PHASE1/PHASE2

Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms

Sponsor: Kimera Labs Inc.

View on ClinicalTrials.gov

Summary

Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.

Official title: A Stratified Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase I/IIa Clinical Trial to Assess the Safety and Efficacy of a Single Intravenous Dose of Isolated, Placental, Mesenchymal Stem Cell-derived Extracellular Vesicles for the Treatment of COVID-19 Symptoms in Adults With Mild to Moderate Illness

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2027-01

Completion Date

2028-12

Last Updated

2026-06-24

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

IV infusion using an isolated, placental, mesenchymal stem cell derived EVs

Single IV infusion of the drug product XoGlo Pro

BIOLOGICAL

Placebo IV administration

Placebo IV infusion of normal saline